TMED - ETF AI Analysis
Top Page
T. Rowe Price Health Care ETF (TMED)
Rating:64Neutral
Price Target:―
Positive Factors
Recent Short-Term Rebound
The ETF has shown a strong gain over the past month, indicating a recent pickup in performance despite earlier weakness.
Focused Health Care Exposure
With nearly all assets in the health care sector, the fund offers targeted exposure to a defensive area that can be more resilient during economic slowdowns.
Established Health Care Leaders in Top Holdings
Several top positions are large, well-known health care companies, which can provide stability and long-term growth potential for the portfolio.
Negative Factors
Heavy Concentration in a Single Sector
Almost all assets are in health care, so the fund may be hit hard if that sector faces regulatory changes or industry-specific challenges.
Weakness in Key Top Holdings
Some of the largest positions, including the biggest holding, have shown weak year-to-date performance, which can drag on the ETF’s overall returns.
Limited Size and Scale
The fund manages a relatively small amount of assets, which can sometimes lead to lower trading volume and wider bid-ask spreads for investors.
TMED vs. SPDR S&P 500 ETF (SPY)
AUM24.76M
RegionGlobal
Expense Ratio0.44%
Beta0.60
IssuerT. Rowe Price
Inception DateJun 11, 2025
Dividend YieldN/A
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume2,447
30 Day Avg. Volume2,164
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
44.24Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering97
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TMED Summary
TMED is the T. Rowe Price Health Care ETF, an actively managed fund that focuses on health care companies rather than tracking a fixed index. It mainly holds U.S. health care stocks, including well-known names like Eli Lilly and UnitedHealth, along with drug makers, medical device firms, and health care service providers. Someone might invest in TMED to tap into the long-term growth potential of medical innovation and to get diversified exposure across many health care businesses in one investment. A key risk is that it is heavily concentrated in the health care sector, so its value can rise or fall sharply with changes in that industry.
How much will it cost me?The T. Rowe Price Health Care ETF (TMED) has an expense ratio of 0.44%, which means you’ll pay $4.40 per year for every $1,000 invested. This is higher than the average for ETFs because it is actively managed, with experts carefully selecting and adjusting the fund’s holdings to try to outperform traditional health care sector indices.
What would affect this ETF?The TMED ETF could benefit from advancements in biotechnology and medical innovation, as well as increasing global demand for health care services driven by aging populations and emerging markets. However, it may face challenges from regulatory changes, patent expirations, or economic downturns that could impact health care spending and the profitability of its top holdings. Additionally, fluctuations in interest rates could affect the broader market and investor sentiment toward health care stocks.
TMED Top 10 Holdings
TMED is very much a health care story, with a heavy tilt toward big U.S. names and a sprinkling of global players. Eli Lilly is doing the heavy lifting, rising on the back of blockbuster drug momentum, while UnitedHealth has been another strong engine for the fund. On the other side, lab and tools giants like Thermo Fisher and Danaher have been losing steam, and device-focused names such as Insulet and Stryker are dragging performance. Overall, the ETF is concentrated in health care innovators, but recent returns are a mixed bag across subsectors.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 16.35% | $3.87M | $1.14T | 58.88% | 72 Outperform | |
| UnitedHealth | 6.50% | $1.54M | $386.29B | 35.84% | 72 Outperform | |
| Gilead Sciences | 4.60% | $1.09M | $162.98B | 22.78% | 78 Outperform | |
| Thermo Fisher | 4.18% | $989.30K | $194.52B | 21.22% | 72 Outperform | |
| Cencora | 3.04% | $718.15K | $57.69B | 2.16% | 70 Neutral | |
| Danaher | 3.00% | $708.59K | $140.09B | -3.23% | 75 Outperform | |
| Intuitive Surgical | 2.66% | $630.07K | $150.88B | -18.96% | 78 Outperform | |
| Alnylam Pharma | 2.63% | $621.18K | $41.76B | 1.29% | 60 Neutral | |
| Insulet | 2.50% | $592.29K | $11.39B | -45.52% | 70 Outperform | |
| Agilent | 2.50% | $592.03K | $36.91B | 8.37% | 73 Outperform |
TMED Technical Analysis
Positive
―
Price Trends
31.56
Positive
30.54
Positive
29.76
Positive
Market Momentum
1.06
Negative
73.28
Negative
85.23
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For TMED, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 33.06, equal to the 50-day MA of 31.56, and equal to the 200-day MA of 29.76, indicating a bullish trend. The MACD of 1.06 indicates Negative momentum. The RSI at 73.28 is Negative, neither overbought nor oversold. The STOCH value of 85.23 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TMED.
TMED Peer Comparison
Comparison Results
Performance Comparison
TMED
T. Rowe Price Health Care ETF
35.05
9.76
38.59%
FMED
Fidelity Disruptive Medicine ETF
―
―
―
MEDI
Harbor Health Care ETF
―
―
―
MEDX
Horizon Kinetics Medical ETF
―
―
―
BMED
Future Health ETF
―
―
―
JDOC
JPMorgan Healthcare Leaders ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents